Distributed Decision Making Area Earthquake Warning System
    51.
    发明申请
    Distributed Decision Making Area Earthquake Warning System 审中-公开
    分布式决策区地震预警系统

    公开(公告)号:US20090303070A1

    公开(公告)日:2009-12-10

    申请号:US12136289

    申请日:2008-06-10

    IPC分类号: G08B21/00

    CPC分类号: G08B27/00 G08B21/10

    摘要: An improved area earthquake warning system based on distributed decision making method, which makes such a system affordable in the region where wired and wireless mobile communication infrastructures are too expensive to build. The present invention can provide seconds, even tens of seconds for users to seek shelter to reduce injuries and lives lost. An exemplary embodiment of the invention described herein comprises a network of earthquake detection sites covering a geographic region with four types of earthquake detection sites. Instead of sending all raw ground motion signals to a remote central processing site, these detection sites send processed earthquake parameters to a nearby alarm site to decide if an earthquake alarm broadcasting should be triggered. This method shortens the response time, decreases the false alarm rate, and provides unlimited scalability. Further more, this invention provides self-check mechanism to eliminate system malfunction time.

    摘要翻译: 一种基于分布式决策方法的改进型地震预警系统,使得有线和无线移动通信基础设施建设成本高昂的地区实现了这种系统的价格。 本发明可以为用户提供几秒甚至几十秒的时间来寻求避难所,减少伤害和生命损失。 本文描述的本发明的示例性实施例包括覆盖具有四种类型的地震检测位置的地理区域的地震检测站点的网络。 这些检测站点不是将所有原始地面运动信号发送到远程中央处理站点,而是将处理过的地震参数发送到附近的报警站点,以决定是否触发地震报警广播。 该方法缩短响应时间,降低误报率,提供无限可扩展性。 此外,本发明提供了自检机制,以消除系统故障时间。

    BIOMARKER ASSAY USING MICROPARTICLE AGGREGATION
    52.
    发明申请
    BIOMARKER ASSAY USING MICROPARTICLE AGGREGATION 审中-公开
    使用微生物聚集的生物标记测定

    公开(公告)号:US20160334396A1

    公开(公告)日:2016-11-17

    申请号:US14855870

    申请日:2015-09-16

    摘要: In various aspects and embodiments, the present invention is directed to versatile, label-free method for the quantitative and qualitative detection of biomarkers and/or other compounds in a fluid sample using functionalized microparticle aggregates. In these methods, micron-scale particles are functionalized to specifically interact with the biomarker being measured and added to the sample to form aggregates, the size and number of which are counted to find a volume fraction and/or number fraction of aggregates in the sample. There is a direct correlation between the volume fraction and number fraction of these aggregates and the concentration of the corresponding biomarker. By comparing the measured volume fraction and/or number fraction of aggregates in the sample to a calibration curve, the concentration of that biomarker may be determined even for biomarkers or other target compounds in samples at very low concentrations, without the need for fluorescence and enzyme labelling of antibodies.

    摘要翻译: 在各个方面和实施方案中,本发明涉及用于使用官能化的微粒聚集体定量和定性检测流体样品中的生物标志物和/或其它化合物的通用的,无标记的方法。 在这些方法中,微米级颗粒被官能化以与被测量的生物标志物特异性相互作用并加入到样品中以形成聚集体,其尺寸和数量被计数以找到样品中的聚集体的体积分数和/或数量分数 。 这些聚集体的体积分数和数量分数与相应生物标志物的浓度之间存在直接相关性。 通过将样品中聚集体的测量体积分数和/或数量分数与校准曲线进行比较,即使对于生物标志物或其它目标化合物,也可以以非常低的浓度测定该生物标志物的浓度,而不需要荧光和酶 标记抗体。

    Eptifibatide preparation method
    53.
    发明授权
    Eptifibatide preparation method 有权
    依替巴肽制备方法

    公开(公告)号:US09394341B2

    公开(公告)日:2016-07-19

    申请号:US14388026

    申请日:2012-08-09

    摘要: An Eptifibatide preparation method with product purity of more than 99.5%, the method comprising: using a solid phase polypeptide synthesis method to prepare eptifibatide resin, conducting acidolysis on the Eptifibatide resin to obtain a crude Eptifibatide linear peptide product, oxidizing to obtain a crude Eptifibatide product, purifying and exchanging salt to obtain an Eptifibatide finished product; the method using the solid phase polypeptide synthesis method to prepare the eptifibatide resin is: using a solid phase coupling synthesis method to sequentially splice a corresponding protective amino acid or a segment in the following sequence onto amino resin, and obtaining the Eptifibatide resin: X—Y-Trp(R1)-Pro-Cys(R2)-amino resin, wherein R1 is Boc or H, R2 is Trt or Acm, X is Mpr(R2)-Harg(R3), R3 is Pbf or H, and Y is Gly-Asp(OtBu).

    摘要翻译: 一种产品纯度超过99.5%的埃非非肽制剂方法,该方法包括:使用固相多肽合成方法制备依替巴肽,在埃替非巴德树脂上进行酸解,得到粗制的依替非巴肽线型肽产物,进行氧化,得到粗制的埃替非巴肽 产品,净化和交换盐,得到Eptifibatide成品; 使用固相多肽合成方法制备埃替非巴特树脂的方法是:使用固相偶联合成方法将相应的保护性氨基酸或以下列顺序的片段顺序地剪接到氨基树脂上,得到埃替非巴德树脂:X- Y-Trp(R1)-Pro-Cys(R2) - 氨基树脂,其中R1是Boc或H,R2是Trt或Acm,X是Mpr(R2)-Harg(R3),R3是Pbf或H,Y 是Gly-Asp(OtBu)。